Hims & Hers Health registró ingresos por debajo de lo esperado en el primer trimestre debido a presiones en sus márgenes.
La empresa está dejando de lado los medicamentos compuestos de GLP-1 para enfocarse en asociaciones de marca con Novo Nordisk y Eli Lilly. Se espera que este cambio afecte a los márgenes a corto plazo, al tiempo que reduce los riesgos legales asociados con la elaboración de compuestos.
Hermès reported a 6% revenue increase in the first quarter of 2026, driven entirely by higher prices amid flat volume growth. The Middle East conflict led to a 6% sales drop in that region and a double-digit decline in its US-traded shares. Analysts view the sell-off as overdone, presenting a buying opportunity for long-term investors.
Reportado por IA
HLS Therapeutics Inc. (TSX: HLS:CA) has published a slide deck for its 2025 fourth-quarter earnings call, released on March 13, 2026, following an earnings summary dated March 12, 2026.
Palantir Technologies Inc. delivered exceptional first-quarter results, with revenue exceeding consensus estimates by 6% and earnings per share nearly 20% above forecasts. The company's revenue grew over 80% year-over-year, outpacing most tech peers. Despite the strong performance, shares did not rally amid valuation concerns.
Reportado por IA
LVMH announced first-quarter sales rose 1% organically to €19.12 billion. Fashion and leather goods sales fell 2% to €9.25 billion, better than the prior quarter but below expectations. The Middle East conflict impacted growth by about 1 percentage point.